---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000135"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:28:04.851085+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold

## Summary
- Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.
- FDA placed IND for SER-252 on clinical hold due to excipient question; not related to active drug.
- Secured up to $20M convertible note/warrant financing; first $5M drawn in September 2025.
- ATM program raised $2.8M net; 474,712 shares issued at avg $6.00 per share.
- Cash $8.6M as of Sept 30; R&D expenses rose to $3.6M from $2.4M year-over-year.

## SEC filing metadata
- accession: 0001708599-25-000135
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/0001708599-25-000135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/ser-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000135
- JSON: https://secwatch.observer/filing/0001708599-25-000135.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.